donepezil has been researched along with Depression in 21 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study explored the feasibility and effectiveness of a short-term (10-week) intervention trial using Donepezil administered alone and combined with intensive language action therapy (ILAT) for the treatment of apathy and depression in ten people with chronic post-stroke aphasia." | 9.69 | Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: A feasibility study. ( Berthier, ML; Dávila, G; Edelkraut, L; Jorge, RE; López-Barroso, D; López-González, FJ; Mohr, B; Pulvermüller, F; Starkstein, SE; Torres-Prioris, MJ, 2023) |
| "Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports." | 8.93 | Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. ( Correll, CU; Lu, RB; Luchini, C; Solmi, M; Stubbs, B; Veronese, N; Zaninotto, L, 2016) |
| "In this study, a Drosophila AD model and SH-SY5Y clles were used to assess the toxicity of SIP3, and APPswe/PS1dE9 (APP/PS1) transgenic mice were used to evaluate the cognitive-behavioral and depression-like behavior effect of SIP3 and donepezil co-treatment on symptoms of AD." | 8.12 | Co-Treatment with the Herbal Medicine SIP3 and Donepezil Improves Memory and Depression in the Mouse Model of Alzheimer's Disease. ( Chin, YW; Choi, H; Kanmani, S; Kim, KK; Kim, KW; Kim, SN; Kim, YM; Koo, BS; Liu, QF; Son, T, 2022) |
| "The results of this study suggested that early induction of donepezil treatment was necessary when apparent cognitive decline was identified during the treatment of geriatric depression." | 7.83 | Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression. ( Hoshino, R; Inoue, J; Ishida, W; Nojima, H; Okamoto, N, 2016) |
| "This study explored the feasibility and effectiveness of a short-term (10-week) intervention trial using Donepezil administered alone and combined with intensive language action therapy (ILAT) for the treatment of apathy and depression in ten people with chronic post-stroke aphasia." | 5.69 | Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: A feasibility study. ( Berthier, ML; Dávila, G; Edelkraut, L; Jorge, RE; López-Barroso, D; López-González, FJ; Mohr, B; Pulvermüller, F; Starkstein, SE; Torres-Prioris, MJ, 2023) |
| " Mood disorders (depression, anxiety and apathy) were significantly decreased in subjects treated with donepezil and choline alphoscerate, while their severity and frequency was increased in the other group." | 5.24 | The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial. ( Amenta, F; Carotenuto, A; Fasanaro, AM; Manzo, V; Rea, R; Ricci, G; Traini, E, 2017) |
| " Significant improvements were observed on the Alzheimer's Disease Assessment Scale-cognitive component-Japanese version and the Neuropsychiatric Inventory depression scores of patients who received the combined therapy with donepezil and NYT (Alzheimer's Disease Assessment Scale-cognitive component-Japanese version, 12 months: P < 0." | 5.22 | Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation. ( Arita, R; Asou, H; Honda, M; Kishi, T; Komatsu, Y; Kudoh, C; Mimura, M, 2016) |
| "Effective counseling and support interventions can reduce symptoms of depression in caregivers when patients are taking donepezil." | 5.13 | A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: effects on caregiver depression. ( Brodaty, H; Burns, A; Mittelman, MS; Wallen, AS, 2008) |
| "Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports." | 4.93 | Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. ( Correll, CU; Lu, RB; Luchini, C; Solmi, M; Stubbs, B; Veronese, N; Zaninotto, L, 2016) |
| "A literature search of MEDLINE (1950-September 2011) was conducted, using the search term depression in combination with cholinesterase inhibitor, donepezil, galantamine, or rivastigmine." | 4.88 | Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. ( Gray, SL; McDermott, CL, 2012) |
| " Symptoms, interventions, and treatment-related adverse events addressed in this issue are management of Alzheimer's agitation with donepezil; needle-free lidocaine powder for minor painful procedures; psychostimulants in depression; anticoagulation for cancer-related venous thromboembolism; effect of waiting for acute pain treatment on risk of chronic pain; and an update on severe cutaneous reactions associated with medications." | 4.85 | Pain and palliative care pharmacotherapy literature summaries and analyses. ( Abernethy, AP; Farrell, TW, 2009) |
| "In this study, a Drosophila AD model and SH-SY5Y clles were used to assess the toxicity of SIP3, and APPswe/PS1dE9 (APP/PS1) transgenic mice were used to evaluate the cognitive-behavioral and depression-like behavior effect of SIP3 and donepezil co-treatment on symptoms of AD." | 4.12 | Co-Treatment with the Herbal Medicine SIP3 and Donepezil Improves Memory and Depression in the Mouse Model of Alzheimer's Disease. ( Chin, YW; Choi, H; Kanmani, S; Kim, KK; Kim, KW; Kim, SN; Kim, YM; Koo, BS; Liu, QF; Son, T, 2022) |
| "In terms of antidepressant drugs prescribed in hospital admission, during stay and discharge, the number of sertraline and venlafaxine prescriptions were associated with the number of VaD patients whilst the number of mirtazapine prescriptions was associated with frontotemporal dementia patients." | 4.12 | Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals. ( Finn, DP; Joshi, A; McClean, PL; Todd, S; Wong-Lin, K, 2022) |
| "The results of this study suggested that early induction of donepezil treatment was necessary when apparent cognitive decline was identified during the treatment of geriatric depression." | 3.83 | Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression. ( Hoshino, R; Inoue, J; Ishida, W; Nojima, H; Okamoto, N, 2016) |
| "Depression is one of the most frequent psychiatric disorders of Alzheimer's disease (AD)." | 1.46 | Silibinin ameliorates anxiety/depression-like behaviors in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus. ( Cui, L; Hattori, S; Hayashi, T; Ikejima, T; Liu, B; Liu, W; Song, X; Tashiro, SI; Ushiki-Kaku, Y; Xu, F; Zhou, B, 2017) |
| "Treatments in Alzheimer's disease include treatment of cognitive impairment and behavioral manifestations (agitation, depression, anxiety, delusions)." | 1.30 | [Drug therapy strategies in Alzheimer's disease]. ( Lacomblez, L, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 5 (23.81) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Li, J | 2 |
| Huang, Y | 1 |
| Gong, Q | 1 |
| Fu, Y | 1 |
| Xu, Y | 1 |
| Huang, J | 1 |
| You, H | 1 |
| Zhang, D | 2 |
| Mao, F | 1 |
| Zhu, J | 1 |
| Wang, H | 1 |
| Zhang, H | 1 |
| Liu, QF | 1 |
| Choi, H | 1 |
| Son, T | 1 |
| Kim, YM | 1 |
| Kanmani, S | 1 |
| Chin, YW | 1 |
| Kim, SN | 1 |
| Kim, KK | 1 |
| Kim, KW | 1 |
| Koo, BS | 1 |
| Joshi, A | 1 |
| Todd, S | 1 |
| Finn, DP | 1 |
| McClean, PL | 1 |
| Wong-Lin, K | 1 |
| Quintana-Hernández, DJ | 3 |
| Rojas-Hernández, J | 3 |
| Santana-Del Pino, A | 3 |
| Céspedes Suárez, C | 3 |
| Pellejero Silva, M | 3 |
| Miró-Barrachina, MT | 3 |
| Ibáñez Fernández, I | 3 |
| Estupiñán López, JA | 3 |
| Borkel, LF | 3 |
| Berthier, ML | 2 |
| Edelkraut, L | 2 |
| López-González, FJ | 2 |
| López-Barroso, D | 2 |
| Mohr, B | 2 |
| Pulvermüller, F | 2 |
| Starkstein, SE | 2 |
| Jorge, RE | 2 |
| Torres-Prioris, MJ | 2 |
| Dávila, G | 2 |
| Akechi, T | 1 |
| Suzuki, M | 1 |
| Hashimoto, N | 1 |
| Yamada, T | 1 |
| Yamada, A | 1 |
| Nakaaki, S | 1 |
| Song, X | 1 |
| Liu, B | 1 |
| Cui, L | 1 |
| Zhou, B | 1 |
| Liu, W | 1 |
| Xu, F | 1 |
| Hayashi, T | 1 |
| Hattori, S | 1 |
| Ushiki-Kaku, Y | 1 |
| Tashiro, SI | 1 |
| Ikejima, T | 1 |
| Diniz, BS | 1 |
| Reynolds, CF | 1 |
| Begley, A | 1 |
| Dew, MA | 1 |
| Anderson, SJ | 1 |
| Lotrich, F | 1 |
| Erickson, KI | 1 |
| Lopez, O | 1 |
| Aizenstein, H | 1 |
| Sibille, EL | 1 |
| Butters, MA | 1 |
| Kudoh, C | 1 |
| Arita, R | 1 |
| Honda, M | 1 |
| Kishi, T | 1 |
| Komatsu, Y | 1 |
| Asou, H | 1 |
| Mimura, M | 1 |
| Inoue, J | 1 |
| Hoshino, R | 1 |
| Nojima, H | 1 |
| Ishida, W | 1 |
| Okamoto, N | 1 |
| Veronese, N | 1 |
| Solmi, M | 1 |
| Luchini, C | 1 |
| Lu, RB | 1 |
| Stubbs, B | 1 |
| Zaninotto, L | 1 |
| Correll, CU | 1 |
| Carotenuto, A | 1 |
| Rea, R | 1 |
| Traini, E | 1 |
| Fasanaro, AM | 1 |
| Ricci, G | 1 |
| Manzo, V | 1 |
| Amenta, F | 1 |
| Mittelman, MS | 1 |
| Brodaty, H | 1 |
| Wallen, AS | 1 |
| Burns, A | 1 |
| Abernethy, AP | 1 |
| Farrell, TW | 1 |
| Katona, C | 1 |
| McDermott, CL | 1 |
| Gray, SL | 1 |
| Gauthier, S | 1 |
| Feldman, H | 1 |
| Hecker, J | 1 |
| Vellas, B | 1 |
| Ames, D | 1 |
| Subbiah, P | 1 |
| Whalen, E | 1 |
| Emir, B | 1 |
| Freund-Levi, Y | 1 |
| Basun, H | 1 |
| Cederholm, T | 1 |
| Faxén-Irving, G | 1 |
| Garlind, A | 1 |
| Grut, M | 1 |
| Vedin, I | 1 |
| Palmblad, J | 1 |
| Wahlund, LO | 1 |
| Eriksdotter-Jönhagen, M | 1 |
| Jakovljevic, M | 1 |
| Vuksan-Cusa, B | 1 |
| Topic, R | 1 |
| Doaga, A | 1 |
| Lee, TJ | 1 |
| Russell, R | 1 |
| Nair, R | 1 |
| Lacomblez, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Maintenance Therapies in Late-Life Depression: MTLD III[NCT00177671] | Phase 4 | 220 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Can Early Counseling and Support for Alzheimer's Disease Caregivers Improve Burden? A Multi-centre Active Randomized Clinical Trial in Local Health Services[NCT02685787] | 230 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | |||
| A 6 Months, Prospective, Open-label, Observational, Non-interventional Clinical Trial to Examine the Efficacy and Safety of Donepezil (Dementis®) Administration in Patients With Dementia.[NCT01772095] | 389 participants (Actual) | Observational | 2013-02-28 | Completed | |||
| Omega-3 Fatty Acid Treatment of 174 Patients With Mild to Moderate Alzheimer's Disease (OmegAD): a Randomized Double-blind Trial[NCT00211159] | 204 participants | Interventional | 2000-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Recurrence of major depressive episodes as determined by SCID/DSM IV: two weeks of low mood and/or anhedonia, together with at least five of the following symptoms: suicidal ideation, low energy, sleep disturbance, appetite disturbance, psychic anxiety or somatic anxiety. In addition, a diagnosis of major depression requires evidence of distress or impairment. (NCT00177671)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Donepezil | 19 |
| Placebo | 11 |
Conversion to dementia was ascertained by the University of Pittsburgh Alzheimer Disease Research Center (ADRC), using data on neuropsychological performance and IADL functioning, as well as other relevant clinical data. Diagnoses were made according to National Alzheimer Coordinating Center criteria. (NCT00177671)
Timeframe: 2 year
| Intervention | Percent of Participants (Number) |
|---|---|
| Donepezil | 10 |
| Placebo | 33 |
The PASS (a performance-based assessment of instrumental activities of daily living)generates a composite measure of 13 cognitive IADL items capturing performance on activities such as shopping, bill paying, medication management, and home safety. We report the percentage of subjects at each assessment point adjudged to have independent functioning. This was determined by a clinician rater observing subjects perform each task and rating them according to predetermined criteria on a 4 point scale, ranging from 0 (unable) to 3 (independent). (NCT00177671)
Timeframe: baseline, year 1 and year 2
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Baseline (N=33; N=34) | Year 1 (N=23; N=25) | Year 2 (N=11; N=17) | |
| Donepezil | 54.10 | 62.16 | 36.67 |
| Placebo | 61.82 | 54.35 | 47.22 |
Cognitive performance was assessed with 17 well established and validated individual tests measuring multiple domains. We transformed raw scores for individual tests into Z-scores using the baseline distribution of a non-depressed, cognitively normal, older adult comparison group (N=36)of similar age, education, and medical health recruited concurrently with the depressed participants. These Z-scores were averaged within each neuropsychological area to produce domain scores and then averaged over all 17 tests to calculate a global cognition performance score. (NCT00177671)
Timeframe: Measured at baseline and Years 1 and 2 in maintenance
| Intervention | Z-score (Mean) | ||
|---|---|---|---|
| Baseline (N=67;N=63) | Year 1 (N=45; N=57) | Year 2 N=42; N=49) | |
| Donepezil | -0.47 | -0.23 | -0.31 |
| Placebo | -0.47 | -0.65 | -0.56 |
4 reviews available for donepezil and Depression
| Article | Year |
|---|---|
Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions.
Topics: Adult; Bipolar Disorder; Case-Control Studies; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2016 |
Pain and palliative care pharmacotherapy literature summaries and analyses.
Topics: Alzheimer Disease; Amphetamines; Anesthetics, Local; Anticoagulants; Antidepressive Agents; Depressi | 2009 |
Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.
Topics: Antidepressive Agents; Cholinesterase Inhibitors; Cognition Disorders; Depression; Donepezil; Drug T | 2012 |
Clinical inquiries. What could be behind your elderly patient's subjective memory complaints?
Topics: Aged; Cognition; Depression; Donepezil; Geriatric Assessment; Ginkgo biloba; Humans; Indans; Memory | 2008 |
8 trials available for donepezil and Depression
| Article | Year |
|---|---|
Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial.
Topics: Aged; Alzheimer Disease; Depression; Donepezil; Humans; Longitudinal Studies; Mindfulness | 2023 |
Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial.
Topics: Aged; Alzheimer Disease; Depression; Donepezil; Humans; Longitudinal Studies; Mindfulness | 2023 |
Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial.
Topics: Aged; Alzheimer Disease; Depression; Donepezil; Humans; Longitudinal Studies; Mindfulness | 2023 |
Mindfulness Prevents Depression and Psychopathology in Elderly People with Mild to Moderate Alzheimer's Disease: A Randomized Clinical Trial.
Topics: Aged; Alzheimer Disease; Depression; Donepezil; Humans; Longitudinal Studies; Mindfulness | 2023 |
Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: A feasibility study.
Topics: Apathy; Aphasia; Depression; Donepezil; Feasibility Studies; Humans; Language; Language Therapy; Tre | 2023 |
Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: A feasibility study.
Topics: Apathy; Aphasia; Depression; Donepezil; Feasibility Studies; Humans; Language; Language Therapy; Tre | 2023 |
Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: A feasibility study.
Topics: Apathy; Aphasia; Depression; Donepezil; Feasibility Studies; Humans; Language; Language Therapy; Tre | 2023 |
Donepezil alone and combined with intensive language-action therapy on depression and apathy in chronic post-stroke aphasia: A feasibility study.
Topics: Apathy; Aphasia; Depression; Donepezil; Feasibility Studies; Humans; Language; Language Therapy; Tre | 2023 |
Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: a longitudinal study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cognitive Dysfunc | 2014 |
Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition | 2016 |
The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.
Topics: Aged; Alzheimer Disease; Anxiety; Apathy; Caregivers; Depression; Donepezil; Double-Blind Method; Fe | 2017 |
A three-country randomized controlled trial of a psychosocial intervention for caregivers combined with pharmacological treatment for patients with Alzheimer disease: effects on caregiver depression.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Australia; Caregivers; Cholinesterase Inhibitors; Counse | 2008 |
Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anxiety; Arousal; Depression; Donepezil; Double-Blind Method; Female; Human | 2002 |
Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Cholin | 2008 |
9 other studies available for donepezil and Depression
| Article | Year |
|---|---|
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antidepressive Agents; Binding Sites; Brain; Choli | 2022 |
Co-Treatment with the Herbal Medicine SIP3 and Donepezil Improves Memory and Depression in the Mouse Model of Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Depression; Diseas | 2022 |
Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals.
Topics: Aged; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Depression; Donepezil; Dothiepin | 2022 |
Different pharmacological responses in late-life depression with subsequent dementia: a case supporting the reserve threshold theory.
Topics: Aged; Antidepressive Agents; Brain; Cholinesterase Inhibitors; Cognitive Reserve; Dementia, Vascular | 2017 |
Silibinin ameliorates anxiety/depression-like behaviors in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anxiety; Autophagy; Brain-Derived Neurotrophic Fa | 2017 |
Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cognition Disorder | 2016 |
Dementia: Does depression predict donepezil response in MCI?
Topics: Cognition Disorders; Dementia; Depression; Donepezil; Humans; Indans; Nootropic Agents; Piperidines | 2009 |
Some treatment dilemmas in rapidly developing dementia: a case report.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cholinesterase Inhibitors; Dementia; Depression; Diseas | 2008 |
[Drug therapy strategies in Alzheimer's disease].
Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Car | 1998 |